title: An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05%: reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis. Emadine Study Group.
abstract: OBJECTIVE
  To compare emedastine ophthalmic solution 0.05% BID to levocabastine ophthalmic suspension 0.05% BID in reducing chemosis, eyelid swelling and other signs and symptoms in subjects with seasonal allergic conjunctivitis.
  
  
  METHODS
  In a randomized, double-masked, parallel controlled study, emedastine ophthalmic solution 0.05% BID was compared to levocabastine ophthalmic suspension 0.05% BID for control of chemosis, eyelid swelling and other parameters in the environmental allergy study model.
  
  
  RESULTS
  At Days 7, 14, 30 and 42, emedastine was significantly better than levocabastine at controlling chemosis and eyelid swelling (p < 0.05). A statistical trend was seen at Day 3 (0.05 < p < 0.10). Results were clinically relevant at Days 30 and 42. Emedastine was also significantly better at reducing redness and itching at Days 7, 14, 30 and 42 (p < 0.05).
  
  
  CONCLUSIONS
  Emedastine is more efficacious than levocabastine in reducing chemosis, eyelid swelling and other efficacy variables associated with seasonal allergic conjunctivitis.
authors.affiliation: Department of Ophthalmology, University of Padua, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Secchi
authors.forename: A
authors.initials: A
authors.lastname: Leonardi
authors.forename: M
authors.initials: M
authors.lastname: Discepola
authors.forename: J
authors.initials: J
authors.lastname: Deschenes
authors.forename: M B
authors.initials: MB
authors.lastname: Abelson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003228:Conjunctiva / Q000187:drug effects; D003233:Conjunctivitis, Allergic / Q000188:drug therapy* / Q000473:pathology; D004311:Double-Blind Method; D004487:Edema / Q000188:drug therapy* / Q000473:pathology; D005141:Eyelid Diseases / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012449:Safety; D012621:Seasons; D016896:Treatment Outcome
chemical_list: D001562:Benzimidazoles; D006634:Histamine H1 Antagonists; D009883:Ophthalmic Solutions; D010880:Piperidines; C043345:emedastine; C047340:levocabastine